IBB250103C160000
- 0.00
- 0.000.00%
iShares Biotechnology ETF Newsroom
Solid Biosciences Stock Jumps 11% Post-market on FDA Update
Looking Into Gilead Sciences's Recent Short Interest
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Vertex Grapples With Bearish Chart As Death Cross Emerges
Alnylam Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
FDA Issues Draft Guidance on Developing Weight Loss Drugs
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Argenx Analyst Ratings
Orna Therapeutics Enters Three-year Strategic Research Collaboration With Vertex Pharmaceuticals; Orna To Receive $65M Upfront Payment And Is Eligible To Receive Up To $635M Milestones
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Healthcare Sector's 2024 Gainers and Losers: Intuitive Surgical, Boston Scientific Tops Chart
Citi's Themes: Top Stocks in AI, Leisure, Fin-tech, Video Gaming, Etc. Vs. Their SA Quant Ratings
Sector Update: Health Care Stocks Edge Higher Premarket Monday
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Regeneron Expands Eye Care Focus With Oxular Buyout
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
How Is The Market Feeling About IQVIA Hldgs?